The news of RBC Capital maintaining its 'Sector Perform' rating on Neurocrine Biosciences and raising the price target is likely to have a positive impact on the company's stock in the short term. Investors may see this as a sign of confidence in the company's performance and future prospects, potentially leading to increased demand for the stock and a rise in its price.